Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New shareholder

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 18, 2024 8:59pm

110 Views

Post# 35997168

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder

And ONCY is a late-stage development company that has "de-risked" its platform asset in the treatment of multiple cancers with orphan, and unmet treatment needs, thus making ONCY a prime late-stage clinical development acquisition candidate for Big Pharma. Do your due diligence before posting again, because you obviously haven't thus far.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec